Trial Profile
Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Glucagon (Primary)
- Indications Hypoglycaemia
- Focus Pharmacodynamics; Proof of concept
- Sponsors XERIS Pharmaceuticals
- 02 Feb 2021 Status changed to discontinued as primary end point was not met.
- 16 Jun 2020 According to results presented at the 80th Annual Scientific Sessions of the American Diabetes Association, long term follow up of this study has been stopped early
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association